Abstract
Hyperoside has a variety of pharmacological activities, including anti-liver injury, anti-depression, anti-inflammatory, and anti-cancer activities. However, the effect of hyperoside on Parkinson’s disease (PD) is still unclear. Therefore, we tried to study the therapeutic effect and mechanism of hyperoside on PD in vivo and in vitro models. Rotenone was used to induce PD rat model and SH-SY5Y cell injury model, and hyperoside was used for intervention. Immunohistochemistry, animal behavior assays, TUNEL and Western blot were constructed to observe the protective effect and related mechanisms of hyperoside in vivo. Cell counting kit-8 (CCK-8), flow cytometry, Rh123 staining and Western blot were used for in vitro assays. Rapamycin (RAP) pretreatment was used in rescue experiments to verify the relationship between hyperoside and autophagy in rotenone-induced SH-SY5Y cells. Hyperoside promoted the number of tyrosine hydroxylase (TH)-positive cells, improved the behavioral defects of rats, and inhibited cell apoptosis in vivo. Different concentrations of hyperoside had no significant effect on SH-SY5Y cell viability, but dramatically reversed the rotenone-induced decrease in cell viability, increased apoptosis and loss of cell mitochondrial membrane potential in vitro. Additionally, hyperoside reversed the regulation of rotenone on the Beclin1, LC3II, Bax, cleaved caspase 3, Cyc and Bcl-2 expressions in rat SNpc tissues and SH-SY5Y cells, while promoted the regulation of rotenone on the P62 and α-synuclcin. Furthermore, RAP reversed the effect of hyperoside on rotenone-induced SH-SY5Y cells. Hyperoside may play a neuroprotective effect in rotenone-induced PD rat model and SH-SY5Y cell model by affecting autophagy.
Similar content being viewed by others
Data Availability
The analysed data sets generated during the study are available from the corresponding author on reasonable request.
References
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15:1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7
Cao J et al (2020) Hyperoside alleviates epilepsy-induced neuronal damage by enhancing antioxidant levels and reducing autophagy. J Ethnopharmacol 257:112884. https://doi.org/10.1016/j.jep.2020.112884
Cerri S, Blandini F (2019) Role of autophagy in Parkinson’s disease. Curr Med Chem 26:3702–3718. https://doi.org/10.2174/0929867325666180226094351
Chen W, Huang Q, Ma S, Li M (2019) Progress in dopaminergic cell replacement and regenerative strategies for Parkinson’s disease. ACS Chem Neurosci 10:839–851. https://doi.org/10.1021/acschemneuro.8b00389
Chia SJ, Tan EK, Chao YX (2020) Historical perspective: models of Parkinson’s disease. Int J Mol Sci 21:84. https://doi.org/10.3390/ijms21072464
Choi BS, Kim H, Lee HJ, Sapkota K, Park SE, Kim S, Kim SJ (2014) Celastrol from “Thunder God Vine” protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson’s disease. Neurochem Res 39:84–96. https://doi.org/10.1007/s11064-013-1193-y
Daubner SC, Le T, Wang S (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508:1–12. https://doi.org/10.1016/j.abb.2010.12.017
Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66:646–661. https://doi.org/10.1016/j.neuron.2010.04.034
Falkenburger BH, Saridaki T, Dinter E (2016) Cellular models for Parkinson’s disease. J Neurochem 139(Suppl 1):121–130. https://doi.org/10.1111/jnc.13618
Fan HH et al (2017) Hyperoside inhibits lipopolysaccharide-induced inflammatory responses in microglial cells via p38 and NFkappaB pathways. Int Immunopharmacol 50:14–21. https://doi.org/10.1016/j.intimp.2017.06.004
Gong Y et al (2017) Hyperoside protects against chronic mild stress-induced learning and memory deficits. Biomed Pharmacother 91:831–840. https://doi.org/10.1016/j.biopha.2017.05.019
Guo X, Zhang Y, Lu C, Qu F, Jiang X (2020) Protective effect of hyperoside on heart failure rats via attenuating myocardial apoptosis and inducing autophagy. Biosci Biotechnol Biochem 84:714–724. https://doi.org/10.1080/09168451.2019.1685369
Han L, Xie YH, Wu R, Chen C, Zhang Y, Wang XP (2017) Traditional Chinese medicine for modern treatment of Parkinson’s disease. Chin J Integr Med 23:635–640. https://doi.org/10.1007/s11655-016-2537-7
Han NR, Go JH, Kim HM, Jeong HJ (2014) Hyperoside regulates the level of thymic stromal lymphopoietin through intracellular calcium signalling. Phytother Res 28:1077–1081. https://doi.org/10.1002/ptr.5099
Johnson ME, Bobrovskaya L (2015) An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 46:101–116. https://doi.org/10.1016/j.neuro.2014.12.002
Karabiyik C, Lee MJ, Rubinsztein DC (2017) Autophagy impairment in Parkinson’s disease. Essays Biochem 61:711–720. https://doi.org/10.1042/EBC20170023
Kin K, Yasuhara T, Kameda M, Date I (2019) Animal models for Parkinson’s disease research: trends in the 2000s. Int J Mol Sci 20:11. https://doi.org/10.3390/ijms20215402
Kwon SH, Lee SR, Park YJ, Ra M, Lee Y, Pang C, Kim KH (2019) Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons. Int J Mol Sci 20:54. https://doi.org/10.3390/ijms20235832
Li HB, Yi X, Gao JM, Ying XX, Guan HQ, Li JC (2008) The mechanism of hyperoside protection of ECV-304 cells against tert-butyl hydroperoxide-induced injury. Pharmacology 82:105–113. https://doi.org/10.1159/000139146
Li ZL et al (2013) The effect of hyperoside on the functional recovery of the ischemic/reperfused isolated rat heart: potential involvement of the extracellular signal-regulated kinase 1/2 signaling pathway. Free Radic Biol Med 57:132–140. https://doi.org/10.1016/j.freeradbiomed.2012.12.023
Liang Y et al (2017) Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy. Neurotoxicology 63:137–145. https://doi.org/10.1016/j.neuro.2017.09.015
Liu J et al (2018) Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy 14:845–861. https://doi.org/10.1080/15548627.2017.1390636
Middleton E, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751
Raza C, Anjum R, Shakeel NUA (2019) Parkinson’s disease: mechanisms, translational models and management strategies. Life Sci 226:77–90. https://doi.org/10.1016/j.lfs.2019.03.057
Reich SG, Savitt JM (2019) Parkinson’s disease. Med Clin North Am 103:337–350. https://doi.org/10.1016/j.mcna.2018.10.014
Shi Y, Qiu X, Dai M, Zhang X, Jin G (2019) Hyperoside attenuates hepatic ischemia-reperfusion injury by suppressing oxidative stress and inhibiting apoptosis in rats. Transplant Proc 51:2051–2059. https://doi.org/10.1016/j.transproceed.2019.04.066
Tan X, Azad S, Ji X (2018) Hypoxic preconditioning protects SH-SY5Y cell against oxidative stress through activation of autophagy. Cell Transpl 27:1753–1762. https://doi.org/10.1177/0963689718760486
Tanner CM et al (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872. https://doi.org/10.1289/ehp.1002839
Wei A et al (2020) Hyperoside protects human umbilical vein endothelial cells against anticardiolipin antibody-induced injury by activating autophagy. Front Pharmacol 11:762. https://doi.org/10.3389/fphar.2020.00762
Wu F, Xu HD, Guan JJ, Hou YS, Gu JH, Zhen XC, Qin ZH (2015) Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease. Neuroscience 284:900–911. https://doi.org/10.1016/j.neuroscience.2014.11.004
Xie W, Jiang Z, Wang J, Zhang X, Melzig MF (2016) Protective effect of hyperoside against acetaminophen (APAP) induced liver injury through enhancement of APAP clearance. Chem Biol Interact 246:11–19. https://doi.org/10.1016/j.cbi.2016.01.004
Zhang X, Du L, Zhang W, Yang Y, Zhou Q, Du G (2017) Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis. Sci Rep 7:9968. https://doi.org/10.1038/s41598-017-07442-y
Zhu X et al (2017) PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int J Oncol 50:835–846. https://doi.org/10.3892/ijo.2017.3873
Acknowledgements
Not applicable
Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81703978, 81102552), the Central Government Guided Local Funding Projects for Science and Technology Development (No. YDZX20201400001483), Outstanding Youth Talents Program of Shanxi Province (No. [2019]35), the Natural Science Foundation of Shanxi Province (No. 201901D111334), the Returned Chinese Scholars Technology Activities Preferred Project, Shanxi Province of China (No. 20200026), the Research Project Supported by Shanxi Scholarship Council (No. 2021-142), Shanxi university Science and technology innovation Project (No. 2019L0724), the Young Scientist Cultivation Program Project, Shanxi University of Chinese Medicine (No. 2021PY-QN-03).
Author information
Authors and Affiliations
Contributions
Substantial contributions to conception and design: HF, YL. Data acquisition, data analysis and interpretation: MS, WX, LS, QW, BZ, JY, XJ, CM, ZC. Drafting the article or critically revising it for important intellectual content: HF, YL, MS, WX, LS, QW, BZ, JY, XJ, CM, ZC. Final approval of the version to be published: HF, YL, MS, WX, LS, QW, BZ, JY, XJ, CM, ZC. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved: HF, YL, MS, WX, LS, QW, BZ, JY, XJ, CM, ZC.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Ethical Approval
Animal assays were permitted by the Ethical Committee of Experimental Animals of Academic Committee of Shanxi University of Traditional Chinese Medicine (AP202004018), and performed in accordance with the guidelines of the China Council on Animal Care and Use. All rats were bred in a SPF-level animal center under standard laboratory conditions.
Consent to Participate
Hyperoside (PHL89227, ≥ 95.0%) was purchased from Phyproof Company (Germany). Rotenone (R8875, ≥ 95.0%) was purchased from Sigma-Aldrich (USA). Specific pathogen-free (SPF) male Sprague–Dawley (SD) rats (240–260 g) were purchased from Jiangsu Ailingfei Biotechnology Co. LTD (China).
Consent for Publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fan, H., Li, Y., Sun, M. et al. Hyperoside Reduces Rotenone-induced Neuronal Injury by Suppressing Autophagy. Neurochem Res 46, 3149–3158 (2021). https://doi.org/10.1007/s11064-021-03404-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-021-03404-z